Skip to main content
Premium Trial:

Request an Annual Quote

Benitec Announces Positive Animal Data with Lung Cancer Drug Candidate

Premium

Benitec Biopharma last week announced that a collaborator generated preclinical data showing that the company’s expressed RNAi technology can be used to boost survival in a orthotopic mouse model of non-small cell lung cancer.

The work, which was conducted by the Children’s Cancer Institute Australia of the University of South Wales, indicated that animals treated with Benitec’s Tribetarna, which targets the beta III tubulin gene, and chemotherapy survived “significantly” longer than those receiving chemotherapy alone.

After sixty days, 50 percent of the mice treated with Benitec’s drug were alive, versus 14 percent in the chemotherapy-only group.

Benitec said it is currently in discussions with a Ground Zero Pharmaceuticals, a US-based clinical research organization, about initiating discussions with the US Food and Drug Administration to test Tribetarna in humans.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.